Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:fragrance
|
| gptkbp:bfsLayer |
7
|
| gptkbp:bfsParent |
gptkb:Clexane
|
| gptkbp:activities |
inhibits factor Xa and factor I Ia
|
| gptkbp:appointed_by |
subcutaneous injection
|
| gptkbp:approves |
gptkb:1993
gptkb:FDA |
| gptkbp:brand |
Lovenox
|
| gptkbp:category |
B
compatible |
| gptkbp:class |
low molecular weight heparin
|
| gptkbp:clinical_trial |
Phase III
hospital and outpatient settings |
| gptkbp:contraindication |
active bleeding
severe renal impairment |
| gptkbp:developed_by |
gptkb:Sanofi
|
| gptkbp:dosage_form |
injection
|
| gptkbp:education |
injection technique
importance of adherence signs of bleeding |
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
sodium salt
|
| https://www.w3.org/2000/01/rdf-schema#label |
enoxaparin sodium
|
| gptkbp:indication |
prophylaxis of venous thromboembolism
treatment of unstable angina |
| gptkbp:ingredients |
C21 H28 N2 O37 S
|
| gptkbp:interacts_with |
antiplatelet agents
thrombolytics NSAI Ds |
| gptkbp:is_available_on |
generic version
|
| gptkbp:is_monitored_by |
anti-Xa levels
platelet count |
| gptkbp:is_used_for |
preventing deep vein thrombosis
treating acute coronary syndrome |
| gptkbp:lifespan |
4 to 5 hours
|
| gptkbp:manager |
subcutaneous
|
| gptkbp:metabolism |
primarily in the liver
|
| gptkbp:packaging |
pre-filled syringes
|
| gptkbp:pharmacokinetics |
dose-dependent
antithrombotic effect |
| gptkbp:price |
varies by region
|
| gptkbp:provides_information_on |
NICE guidelines
ACCP guidelines |
| gptkbp:research |
ongoing studies for new indications
|
| gptkbp:safety_features |
generally safe when used as directed
|
| gptkbp:side_effect |
bleeding
hypersensitivity thrombocytopenia local reactions at injection site |
| gptkbp:storage |
room temperature
|
| gptkbp:traded_on |
gptkb:Clexane
|
| gptkbp:weight |
6000 to 8000 Da
|